
TARA Stock Forecast & Price Target
TARA Analyst Ratings
Bulls say
Protara Therapeutics Inc has demonstrated a strengthened efficacy profile for its lead program TARA-002, with 6-month data showing improvements over initial 3-month results, indicating a 100% durability and an 80% salvage rate upon re-induction. Additionally, the Phase 2 trial of intravenous (IV) choline chloride revealed significant improvements in liver health compared to placebo, suggesting robust potential for this therapy in treating intestinal failure associated liver disease. The combination of TARA-002's safety and administration benefits, along with the promising trial results, positions the company favorably within the competitive landscape of treatment options for cancer and rare diseases.
Bears say
Protara Therapeutics Inc reported a significant net loss of $12.7 million, or $0.48 per share, in the fourth quarter of 2024, which raises concerns about its financial sustainability given its current cash burn rate. Despite early positive signals for TARA-002 in non-muscle invasive bladder cancer (NMIBC), the company's stock is trading at a steep discount compared to competitors, indicating potential investor skepticism about its long-term value. Furthermore, the limited efficacy of intravenous choline chloride in addressing intestinal failure-associated liver disease (IFALD) and its abundance in normal diets suggest challenges in differentiating the therapy in a competitive landscape, further contributing to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TARA Analyst Forecast & Price Prediction
Start investing in TARA
Order type
Buy in
Order amount
Est. shares
0 shares